Healthcare Markets

Health care is bought and sold under strange conditions.

10 frameworks, from 1963 to today · Health Economics · Economics

still a working view ended · each leads to its entry below

Overview

Health care is bought and sold under strange conditions1. The patient usually does not know what treatment he needs; the doctor both advises the purchase and supplies it; and a third party—an insurer or a government—often pays most of the bill1. Healthcare markets is the branch of health economics that studies how these peculiar exchanges work: how prices, quantities, quality, and risk are determined when information is lopsided and payment is pooled. Its history is a sequence of attempts to make ordinary economic tools fit a market where the buyer is often not the chooser, the seller often defines the need, and the product can be a matter of life and death.

The mid-twentieth-century puzzle: demand without a normal buyer

The founding problem was demand. In an ordinary market, a consumer who wants a good buys it. In medicine, the patient seeks care because he is ill, but the physician decides what care is needed1. Economists in the 1950s and 1960s therefore asked whether the standard theory of consumer demand could apply at all.

The most influential answer came from Kenneth Arrow's 1963 essay "Uncertainty and the Welfare Economics of Medical Care."1 Arrow argued that the defining feature of medical markets is uncertainty about when illness will strike and what treatment will work, combined with a deep information gap between physician and patient1. Because the patient cannot judge the quality of advice, he relies on trust and on professional norms; because illness is unpredictable, insurance arises to pool risk. Arrow's essay established the information asymmetry framing: the market for care is not a standard competitive market but one shaped by agency—the physician acts on the patient's behalf—and by the institutions, such as licensure and nonprofit hospitals, that societies build to manage that agency.

A parallel line of work asked why people demand health at all. Michael Grossman's 1972 model of health capital treated health as a durable stock that people invest in—through medical care, diet, exercise—and that depreciates with age. Health is not consumed for its own sake but as an input into producing healthy days. The model made a striking prediction: as people age, the cost of maintaining health rises, so they invest less and health declines; and higher wages raise the value of healthy time, so richer people invest more. This health capital framework turned the demand for care into a derived demand—derived from the demand for health itself—and gave economists a way to think about prevention, aging, and the returns to medical spending1.

Supplier-induced demand and the agency problem

If the physician decides what the patient needs, what stops the physician from recommending more care than necessary? This question produced the supplier-induced demand literature, developed most prominently by Victor Fuchs and by Robert Evans in the 1970s and 1980s. The claim was that physicians, facing a target income or responding to fee schedules, could shift the demand curve for their own services—recommending extra visits or tests that a fully informed patient would not choose. The evidence was contested: studies of fee changes and utilization produced mixed results, and critics argued that observed correlations could reflect unmeasured patient need. But the idea forced the field to take the agency relationship seriously as an economic problem, not merely an ethical one.

The policy implication was direct: how you pay the physician changes what he does. Fee-for-service rewards volume; capitation—a fixed payment per patient—rewards restraint but risks under-provision. This tension between moral hazard (once insured, people use more care because someone else pays) and supply-side incentives became the organizing axis of payment policy.

Insurance economics: moral hazard and adverse selection

Insurance itself became a central object of study. The moral hazard problem—the tendency of insured people to use more care because the marginal cost to them is low—was formalized in the 1960s and 1970s, and it received its most famous empirical test in the RAND Health Insurance Experiment (1974–1982), a randomized trial that assigned families to different cost-sharing plans. The finding that higher copayments reduced spending without large measured harms to health (except among the poorest and sickest) gave the field its benchmark estimate of demand response.

The second problem was adverse selection: if insurers charge a uniform premium, sicker people are more likely to buy generous coverage, driving up costs and pushing healthy people out12. This dynamic, analyzed in the classic insurance literature and applied to health by economists in the 1970s and 1980s, explained why markets for individual insurance can unravel and why employers and governments pool risk. The policy response—risk adjustment, paying insurers more for sicker enrollees—became a technical field of its own, with formulas that use diagnoses to predict costs. Risk adjustment is the regulatory answer to selection: it tries to make insurers compete on efficiency rather than on attracting the healthy.

Managed care and selective contracting

In the 1980s and 1990s, the American health system experimented with managed care: health maintenance organizations (HMOs) and preferred provider organizations that combined insurance with care management3. The economic logic was selective contracting—insurers negotiating discounted prices with chosen providers and steering patients toward them—and utilization review, which policed the physician's decisions3. Managed care did slow spending growth in the 1990s, but it provoked a backlash from patients and physicians who resented restrictions, and its market share and intensity waxed and waned.

The theoretical companion was managed competition, associated with Alain Enthoven in the late 1970s and 1980s: a framework in which competing insurers, regulated to prevent selection, would bargain with providers and compete for enrollees on price and quality. Managed competition shaped the design of the Dutch and Swiss insurance systems and, in a different form, the American Affordable Care Act's insurance marketplaces. Its central claim was that competition could be made to work if the rules forced insurers to bear the cost of their choices and prevented them from cherry-picking the healthy.

Empirical industrial organization: measuring market power and prices

From the 1980s onward, health economists increasingly borrowed the tools of empirical industrial organization—the branch of economics that estimates how firms compete, how prices are set, and how mergers affect consumers. In health care, this meant studying hospital competition, measuring the effect of concentration on prices, and estimating demand for insurance plans. The question was no longer only "what is the theory of the physician's behavior?" but "what do the data say about how much market power hospitals have, and what happens to prices when they merge?"

This empirical turn was accelerated by a methodological revolution. Quasi-experimental causal identification—using natural experiments, policy discontinuities, and instrumental variables to isolate causal effects—became the field's dominant style. The classic example is the work of Jonathan Gruber and others on the Oregon Health Insurance Experiment (a lottery that assigned Medicaid coverage) and on Massachusetts health reform, which used policy variation to estimate the effects of insurance on utilization and health. The same toolkit was applied to hospital mergers, payment reforms, and pharmaceutical pricing. The shift was from describing correlations to credibly estimating what caused what.

Value-based payment and the present

The most recent turn is value-based payment: paying providers for outcomes or quality rather than volume. Pay-for-performance schemes, accountable care organizations, and bundled payments all attempt to align the physician's financial incentive with the patient's interest. The evidence is mixed—many programs produce modest effects—but the idea has become central to policy debates in the United States, the United Kingdom, and elsewhere.

Today the field is a hybrid. It retains the Arrow–Grossman theoretical core: information asymmetry, agency, health capital, and insurance selection. It has absorbed the empirical industrial organization toolkit: structural estimation of demand and supply, merger analysis, and quasi-experimental evaluation. And it is increasingly concerned with the design of payment and regulation—risk adjustment, managed competition, value-based contracts—as the practical instruments for making a market with strange properties behave better. The open questions are the old ones in new form: how much care is induced by the supplier rather than needed by the patient; how to pool risk without destroying incentives; and whether competition among insurers and providers can be harnessed without sacrificing equity or quality.

References

  1. Health economics (introduction, Healthcare markets, History, Healthcare demand), Wikipedia
  2. Adverse selection, Wikipedia
  3. Managed care, Wikipedia

The frameworks of Healthcare Markets

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1963-Present

    Information asymmetry and agency

    How does lopsided information shape medical exchange?

    Fly to its tower in Nousfarer

  2. 1965-Present

    Insurance economics of moral hazard and adverse selection

    Why does insurance change what people buy and who buys it?

    Fly to its tower in Nousfarer

  3. 1970-1995

    Supplier-induced demand

    Do doctors create the demand for their own services?

    Fly to its tower in Nousfarer

  4. 1972-Present

    Grossman model of health demand

    Why do people invest in their own health?

    Fly to its tower in Nousfarer

  5. 1978-Present

    Managed competition

    Can regulated competition among insurers control costs?

    Fly to its tower in Nousfarer

  6. 1980-2000

    Managed care

    Can insurers manage care to restrain spending?

    Fly to its tower in Nousfarer

  7. 1985-Present

    Empirical industrial organization

    How much market power do hospitals and insurers have?

    Fly to its tower in Nousfarer

  8. 1990-Present

    Risk adjustment

    How should insurers be paid for sicker enrollees?

    Fly to its tower in Nousfarer

  9. 1995-Present

    Quasi-experiment

    What actually causes what in health policy?

    Fly to its tower in Nousfarer

  10. 2000-Present

    Value-based payment

    Does paying for value improve care?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Information asymmetry and agencyInsurance economics of moral hazard a…Supplier-induced demandGrossman model of health demandManaged competitionManaged careEmpirical industrial organizationRisk adjustmentQuasi-experimentValue-based payment

Beyond the field

Where Healthcare Markets's ideas came from in other fields, and what they led to there: the strongest 12 of 34 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Healthcare Markets is a planet in Nousfarer

Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.

Land on Healthcare Markets

Related fields

Fields its ideas are linked to

More in Health Economics

See where Healthcare Markets sits on the Map of Human Knowledge